Medtronic Renal Denervation System Provides Durable Blood Pressure Benefits In Longest Trial To Date
This article was originally published in The Gray Sheet
Executive Summary
The latest results from Medtronic’s SYMPLICITY HTN-2 trial show that patients treated for severe hypertension with the company’s Symplicity radio frequency renal denervation system showed a sustained reduction in blood pressure. The firm also announced the start of a renal denervation trial in patients with moderate hypertension.
You may also be interested in...
Renal Denervation Downer: Medtronic’s Pivotal Trial Misses Efficacy Endpoint
The firm’s SYMPLICITY HTN-3 trial failed to meet its primary efficacy endpoint, scuttling Medtronic’s plans to earn a PMA for renal denervation this year. The primary investigator for the trial acknowledges in an interview that the finding raises serious questions for the future of renal denervation in hypertension.
Renal Denervation Downer: Medtronic’s Pivotal Trial Misses Efficacy Endpoint
The firm’s SYMPLICITY HTN-3 trial failed to meet its primary efficacy endpoint, scuttling Medtronic’s plans to earn a PMA for renal denervation this year. The primary investigator for the trial acknowledges in an interview that the finding raises serious questions for the future of renal denervation in hypertension.
Research Briefs: Medtronic’s New Renal Denervation Trial; CPAP Combats Hypertension; Prosigna Breast Cancer Assay
Medtronic launches the SYMPLICITY HTN-4 trial in moderate hypertension patients. Trial shows CPAP for sleep-apnea patients can also improve blood pressure. The information provided by NanoString’s breast cancer assay could help patients avoid unnecessary chemotherapy.